IMMUNOTHERAPEUTIC AGENT AND IMMUNOTHERAPY FOR PANCREATIC CANCER

摘要

Disclosed are an immunotherapeutic agent and an immunotherapy for prolonging the survival time of a pancreatic cancer patient.Specifically disclosed is an immunotherapy for pancreatic cancer, which is characterized by comprising the steps of: culturing autologous peripheral blood lymphocytes collected from a pancreatic cancer patient while stimulating the autologous peripheral blood lymphocytes with an anti-CD3 antibody and an anti-CD52 antibody, thereby producing an immunotherapeutic agent; and administering the immunotherapeutic agent to a pancreatic cancer patient at least four times, wherein at least 15 × 109 activated lymphocytes are contained in a unit dose for the administration, CD3-CD56+ NK cells make up at least 30% of the activated lymphocytes, and the administration is performed in a pancreatic cancer patient who has at least one state selected from specific multiple immunocompromized states.